Exciting News from Sana Biotechnology
Sana Biotechnology, Inc. (NASDAQ: SANA), a leading company in the field of engineered cell therapies, has recently announced its plans to showcase its innovations and strategies at two renowned investor conferences this December. The company aims to provide significant insights into its business operations and the impact of its research initiatives, led by none other than Steve Harr, the President and Chief Executive Officer.
Conference Participation Details
Sana Biotechnology will be part of the Citi 2024 Global Healthcare Conference, where it is scheduled to participate in a panel discussion on December 3, 2024, at 2:30 p.m. ET. This event will provide a platform for discussing the latest advancements in healthcare and biotechnology, showcasing how Sana is at the forefront of these innovations.
The following day, on December 4, at 2:35 p.m. ET, Sana will present at the 7th Annual Evercore ISI HealthCONx Conference. Here, the emphasis will be on the company's vision for engineered cell therapies and how they hold the potential to revolutionize patient treatment.
Accessing the Webcasts
Investors and interested parties can catch these presentations live via Sana's Investor Relations webpage. After the events, replays of both presentations will be made available on the site for 30 days, allowing audiences to revisit important points and updates shared by the company's leadership.
About Sana Biotechnology
At its core, Sana Biotechnology is dedicated to changing lives through the power of engineered cells. The company envisions a future where patients can benefit from advanced therapies that repair and control genes, restore missing or damaged cells, and ensure these innovative solutions are accessible to all. Sana’s team comprises passionate individuals committed to building a transformative enterprise that challenges the existing paradigms of disease treatment.
Sana's Commitment to Change
Sana Biotechnology isn't just about presenting at investor conferences; it’s about making a lasting impact on the healthcare landscape. The company has a vibrant operational presence across various cities in the United States, including Seattle, Cambridge, South San Francisco, Bothell, and Rochester. Such geographic diversity reflects Sana's comprehensive approach to development and innovation in biotechnology.
Engaging with the Community
The firm actively encourages ongoing communication with its stakeholders and the wider community. Interested investors and media representatives can reach out to Sana's dedicated Investor Relations team. The contact details are provided for both investor and media inquiries, ensuring that all interested parties have a clear avenue to engage.
Investor Relations Contact Information
For investor and media relations, Nicole Keith is the point of contact. She can be reached via email at investor.relations@sana.com or media@sana.com.
Frequently Asked Questions
What is Sana Biotechnology focused on?
Sana Biotechnology is dedicated to changing the landscape of patient treatment by developing engineered cell therapies.
What conferences will Sana Biotechnology present at?
Sana will present at the Citi 2024 Global Healthcare Conference and the 7th Annual Evercore ISI HealthCONx Conference in December.
Who will represent Sana at these conferences?
Steve Harr, the President and CEO of Sana Biotechnology, will lead the presentations.
How can I access the conference presentations?
The webcasts of the presentations will be available on Sana's Investor Relations page.
What is the vision of Sana Biotechnology?
Sana’s vision includes repairing genes, replacing damaged cells, and making therapies accessible to patients worldwide.
